Published on October 12, 2016

Indian pharmaceutical sector accounts for around 2.4 per cent of the global pharmaceutical industry in value terms and 10 percent in volume terms.

Indian market players have group of scientists and engineers who turn the industry further to an even higher level. Currently more than 80 per cent of the antiretroviral drugs used globally to fight AIDS are supplied by Indian pharmaceutical firms, said by market players.

As per the recent market report, India has sustained its lead over China in pharmaceutical exports with a year-on-year growth of 11.44 per cent in FY 2015-16. Third largest drug maker Lupin Limited plans to file its first biosimilar Etanercept for approval in Japan, in 2017.

As per the report, Indian pharmaceutical products sales have been increased by around 12.8% in the September quarter. Some market analyst said that if the domestic market sustains this stimulation in growth, companies can go well easier in FY17. The quarter end result gives confidence that industry is going well and getting back on its feet.

Indian pharma sector is anticipated to go up in near term with the increasing consumer spending, and raising healthcare insurance among others. Apart from this, the Indian government has done lots of work to diminish costs and preamble of generic drugs into the market is expected to benefit the Indian pharmaceutical companies.